Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:CLYM NASDAQ:CRMD NASDAQ:IMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$2.07-1.4%$2.13$0.98▼$4.46$724.83M0.467.98 million shs4.80 million shsCLYMClimb Bio$12.30+1.0%$10.57$1.18▼$12.58$697.46M0.091.24 million shs1.19 million shsCRMDCorMedix$8.60-2.5%$8.02$6.13▼$16.89$691.95M1.461.24 million shs1.27 million shsIMDXOncocyte$5.37-0.6%$5.15$2.33▼$8.51$174.37M1.79280,357 shs105,855 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics+5.00%+8.25%+5.00%-4.98%+70.73%CLYMClimb Bio+6.38%+6.01%+10.73%+82.34%+906.61%CRMDCorMedix+1.73%+2.68%+10.53%+36.53%-35.19%IMDXOncocyte-0.74%-5.26%-11.33%+35.00%+539,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$2.07-1.4%$2.13$0.98▼$4.46$724.83M0.467.98 million shs4.80 million shsCLYMClimb Bio$12.30+1.0%$10.57$1.18▼$12.58$697.46M0.091.24 million shs1.19 million shsCRMDCorMedix$8.60-2.5%$8.02$6.13▼$16.89$691.95M1.461.24 million shs1.27 million shsIMDXOncocyte$5.37-0.6%$5.15$2.33▼$8.51$174.37M1.79280,357 shs105,855 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics+5.00%+8.25%+5.00%-4.98%+70.73%CLYMClimb Bio+6.38%+6.01%+10.73%+82.34%+906.61%CRMDCorMedix+1.73%+2.68%+10.53%+36.53%-35.19%IMDXOncocyte-0.74%-5.26%-11.33%+35.00%+539,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.69Moderate Buy$8.52311.70% UpsideCLYMClimb Bio 3.07Buy$21.7376.64% UpsideCRMDCorMedix 2.75Moderate Buy$15.0074.42% UpsideIMDXOncocyte 2.00Hold$12.00123.46% UpsideCurrent Analyst Ratings BreakdownLatest IMDX, ALLO, CRMD, and CLYM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026CLYMClimb Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$17.006/11/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $20.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.005/15/2026CRMDCorMedix Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/14/2026CRMDCorMedix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/12/2026CLYMClimb Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.005/8/2026CLYMClimb Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$15.00 ➝ $17.005/6/2026CLYMClimb Bio Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$21.005/6/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $19.00(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$20K35,723.03N/AN/A$1.30 per share1.59CLYMClimb BioN/AN/AN/AN/A$3.36 per shareN/ACRMDCorMedix$311.71M2.16$2.00 per share4.31$5.14 per share1.67IMDXOncocyte$4.05M42.81N/AN/A($1.10) per share-4.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$190.89M-$0.77N/AN/AN/AN/A-56.45%-40.36%8/12/2026 (Estimated)CLYMClimb Bio-$59.85M-$0.78N/AN/AN/AN/A-31.45%-30.39%8/11/2026 (Estimated)CRMDCorMedix$163.05M$2.134.0447.78N/A45.25%45.57%24.76%8/6/2026 (Estimated)IMDXOncocyte-$50.22M-$1.48N/AN/AN/A-2,454.64%N/A-96.96%N/ALatest IMDX, ALLO, CRMD, and CLYM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CRMDCorMedix$0.35$0.43+$0.08$0.43$104.96 million$127.43 million5/13/2026Q1 2026ALLOAllogene Therapeutics-$0.19-$0.18+$0.01-$0.18$0.00 millionN/A5/13/2026Q1 2026IMDXOncocyteN/A-$0.28N/A-$0.12N/A$0.03 million5/7/2026Q1 2026CLYMClimb Bio-$0.26-$0.20+$0.06-$0.20N/AN/A3/26/2026Q4 2025IMDXOncocyteN/A-$0.27N/A-$0.72N/A$1.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/ACLYMClimb BioN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/AIMDXOncocyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.659.65CLYMClimb BioN/A27.8627.86CRMDCorMedix0.332.972.74IMDXOncocyteN/A2.542.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%CLYMClimb Bio69.76%CRMDCorMedix34.18%IMDXOncocyte55.35%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%CLYMClimb Bio2.60%CRMDCorMedix3.50%IMDXOncocyte2.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310345.15 million299.60 millionOptionableCLYMClimb Bio957.26 million55.77 millionN/ACRMDCorMedix3078.45 million75.71 millionOptionableIMDXOncocyte12032.29 million31.58 millionN/AIMDX, ALLO, CRMD, and CLYM HeadlinesRecent News About These CompaniesiMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research GrantJune 22 at 2:07 PM | globenewswire.comFavorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical ChemistryJune 16, 2026 | globenewswire.comIMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of TransplantationJune 11, 2026 | globenewswire.comInsight Molecular Diagnostics Inc. (IMDX) Shareholder/Analyst Call Prepared Remarks TranscriptJune 11, 2026 | seekingalpha.comiMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant CongressJune 9, 2026 | globenewswire.comInsight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comIMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure CommercializationMay 13, 2026 | globenewswire.comiMDx to Release First Quarter 2026 Results on May 13, 2026May 6, 2026 | globenewswire.comInsider Buying: Oncocyte (NASDAQ:IMDX) Major Shareholder Acquires 38,880 Shares of StockApril 28, 2026 | insidertrades.comBroadwood Partners, L.P. Purchases 40,114 Shares of Oncocyte (NASDAQ:IMDX) StockApril 21, 2026 | insidertrades.comReal-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure AssayApril 14, 2026 | globenewswire.comInsight Molecular Diagnostics Inc. (IMDX) Q4 2025 Earnings Call TranscriptMarch 26, 2026 | seekingalpha.comIMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 ResultsMarch 26, 2026 | globenewswire.comiMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare ConferenceMarch 20, 2026 | globenewswire.comSecond Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model ScoreMarch 13, 2026 | globenewswire.comInsight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA SubmissionMarch 3, 2026 | globenewswire.comBroadwood Partners, L.P. Acquires 521,739 Shares of Oncocyte (NASDAQ:IMDX) StockFebruary 13, 2026 | insidertrades.comiMDx Announces $26.0 Million Registered Direct OfferingFebruary 11, 2026 | globenewswire.comIMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant MonitoringJanuary 13, 2026 | globenewswire.comiMDx Announces “JPM Week” and “BTIG Snowbird” Conference ParticipationJanuary 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?By Ryan Hasson | June 2, 2026Robinhood Wants a Bigger Role in IPOs—Here's Why It MattersBy Leo Miller | June 14, 2026IMDX, ALLO, CRMD, and CLYM Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$2.07 -0.03 (-1.43%) Closing price 04:00 PM EasternExtended Trading$2.07 0.00 (0.00%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Climb Bio NASDAQ:CLYM$12.30 +0.12 (+0.99%) Closing price 04:00 PM EasternExtended Trading$12.28 -0.02 (-0.16%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.CorMedix NASDAQ:CRMD$8.60 -0.22 (-2.49%) Closing price 04:00 PM EasternExtended Trading$8.73 +0.13 (+1.50%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Oncocyte NASDAQ:IMDX$5.37 -0.03 (-0.56%) Closing price 04:00 PM EasternExtended Trading$5.18 -0.19 (-3.61%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
